nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—CYP1A1—head and neck cancer	0.39	0.615	CbGaD
Thalidomide—PTGS2—head and neck cancer	0.244	0.385	CbGaD
Thalidomide—FGFR2—skull—head and neck cancer	0.00559	0.119	CbGeAlD
Thalidomide—FGFR2—exocrine gland—head and neck cancer	0.00259	0.055	CbGeAlD
Thalidomide—NFKB1—mouth—head and neck cancer	0.00258	0.0547	CbGeAlD
Thalidomide—FGFR2—mouth—head and neck cancer	0.00194	0.0411	CbGeAlD
Thalidomide—NFKB1—parotid gland—head and neck cancer	0.00179	0.0381	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—head and neck cancer	0.00173	0.383	CrCbGaD
Thalidomide—NFKB1—saliva-secreting gland—head and neck cancer	0.00172	0.0365	CbGeAlD
Thalidomide—FGFR2—neck—head and neck cancer	0.00165	0.0351	CbGeAlD
Thalidomide—Pomalidomide—PTGS2—head and neck cancer	0.0016	0.356	CrCbGaD
Thalidomide—NFKB1—connective tissue—head and neck cancer	0.00158	0.0335	CbGeAlD
Thalidomide—CRBN—parotid gland—head and neck cancer	0.0015	0.0319	CbGeAlD
Thalidomide—PTGS2—cartilage tissue—head and neck cancer	0.00145	0.0308	CbGeAlD
Thalidomide—CRBN—saliva-secreting gland—head and neck cancer	0.00144	0.0306	CbGeAlD
Thalidomide—NFKB1—trachea—head and neck cancer	0.00133	0.0282	CbGeAlD
Thalidomide—FGFR2—saliva-secreting gland—head and neck cancer	0.00129	0.0274	CbGeAlD
Thalidomide—FGFR2—connective tissue—head and neck cancer	0.00119	0.0252	CbGeAlD
Thalidomide—Menadione—CYP1A1—head and neck cancer	0.00118	0.261	CrCbGaD
Thalidomide—NFKB1—lymphoid tissue—head and neck cancer	0.00115	0.0245	CbGeAlD
Thalidomide—TNF—lymph node—head and neck cancer	0.00114	0.0243	CbGeAlD
Thalidomide—FGFR2—epithelium—head and neck cancer	0.00113	0.0239	CbGeAlD
Thalidomide—CRBN—trachea—head and neck cancer	0.00111	0.0236	CbGeAlD
Thalidomide—NFKB1—thyroid gland—head and neck cancer	0.00105	0.0223	CbGeAlD
Thalidomide—CRBN—lymphoid tissue—head and neck cancer	0.000968	0.0206	CbGeAlD
Thalidomide—NFKB1—head—head and neck cancer	0.00093	0.0198	CbGeAlD
Thalidomide—CRBN—thyroid gland—head and neck cancer	0.000879	0.0187	CbGeAlD
Thalidomide—FGFR2—thyroid gland—head and neck cancer	0.000787	0.0167	CbGeAlD
Thalidomide—CRBN—head—head and neck cancer	0.00078	0.0166	CbGeAlD
Thalidomide—CYP1A1—mouth—head and neck cancer	0.0007	0.0149	CbGeAlD
Thalidomide—FGFR2—head—head and neck cancer	0.000699	0.0148	CbGeAlD
Thalidomide—NFKB1—lymph node—head and neck cancer	0.000651	0.0138	CbGeAlD
Thalidomide—PTGS2—mouth—head and neck cancer	0.000588	0.0125	CbGeAlD
Thalidomide—CRBN—lymph node—head and neck cancer	0.000546	0.0116	CbGeAlD
Thalidomide—CYP1A1—parotid gland—head and neck cancer	0.000488	0.0104	CbGeAlD
Thalidomide—CYP1A1—epithelium—head and neck cancer	0.000407	0.00865	CbGeAlD
Thalidomide—Bone pain—Docetaxel—head and neck cancer	0.000399	0.00242	CcSEcCtD
Thalidomide—Cardiac failure—Fluorouracil—head and neck cancer	0.000394	0.00239	CcSEcCtD
Thalidomide—Lethargy—Fluorouracil—head and neck cancer	0.000392	0.00238	CcSEcCtD
Thalidomide—Osteoarthritis—Fluorouracil—head and neck cancer	0.000384	0.00234	CcSEcCtD
Thalidomide—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.000384	0.00234	CcSEcCtD
Thalidomide—Pulmonary embolism—Docetaxel—head and neck cancer	0.000382	0.00232	CcSEcCtD
Thalidomide—Hepatocellular injury—Docetaxel—head and neck cancer	0.000382	0.00232	CcSEcCtD
Thalidomide—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.000382	0.00232	CcSEcCtD
Thalidomide—PTGS1—connective tissue—head and neck cancer	0.000377	0.00801	CbGeAlD
Thalidomide—Colitis—Docetaxel—head and neck cancer	0.000367	0.00223	CcSEcCtD
Thalidomide—Cardiac arrest—Fluorouracil—head and neck cancer	0.000365	0.00222	CcSEcCtD
Thalidomide—Skin exfoliation—Docetaxel—head and neck cancer	0.000365	0.00222	CcSEcCtD
Thalidomide—Candida infection—Docetaxel—head and neck cancer	0.000365	0.00222	CcSEcCtD
Thalidomide—Ataxia—Fluorouracil—head and neck cancer	0.000361	0.0022	CcSEcCtD
Thalidomide—PTGS2—connective tissue—head and neck cancer	0.00036	0.00765	CbGeAlD
Thalidomide—CYP1A1—trachea—head and neck cancer	0.00036	0.00765	CbGeAlD
Thalidomide—Neuropathy—Docetaxel—head and neck cancer	0.000359	0.00218	CcSEcCtD
Thalidomide—PTGS1—epithelium—head and neck cancer	0.000358	0.0076	CbGeAlD
Thalidomide—Alopecia—Vinblastine—head and neck cancer	0.000358	0.00218	CcSEcCtD
Thalidomide—Dry skin—Fluorouracil—head and neck cancer	0.000352	0.00214	CcSEcCtD
Thalidomide—Oesophagitis—Docetaxel—head and neck cancer	0.000349	0.00212	CcSEcCtD
Thalidomide—PTGS2—epithelium—head and neck cancer	0.000342	0.00727	CbGeAlD
Thalidomide—Lightheadedness—Docetaxel—head and neck cancer	0.000342	0.00208	CcSEcCtD
Thalidomide—Pulmonary oedema—Docetaxel—head and neck cancer	0.00034	0.00207	CcSEcCtD
Thalidomide—Muscular weakness—Fluorouracil—head and neck cancer	0.000339	0.00206	CcSEcCtD
Thalidomide—Angiopathy—Hydroxyurea—head and neck cancer	0.000335	0.00204	CcSEcCtD
Thalidomide—Dysphagia—Fluorouracil—head and neck cancer	0.000332	0.00202	CcSEcCtD
Thalidomide—Sepsis—Docetaxel—head and neck cancer	0.000331	0.00202	CcSEcCtD
Thalidomide—Chills—Hydroxyurea—head and neck cancer	0.000331	0.00201	CcSEcCtD
Thalidomide—Eosinophilia—Fluorouracil—head and neck cancer	0.000329	0.002	CcSEcCtD
Thalidomide—Ill-defined disorder—Vinblastine—head and neck cancer	0.000327	0.00199	CcSEcCtD
Thalidomide—Alopecia—Hydroxyurea—head and neck cancer	0.000326	0.00198	CcSEcCtD
Thalidomide—Anaemia—Vinblastine—head and neck cancer	0.000326	0.00198	CcSEcCtD
Thalidomide—Angina pectoris—Fluorouracil—head and neck cancer	0.000323	0.00197	CcSEcCtD
Thalidomide—Thrombophlebitis—Docetaxel—head and neck cancer	0.00032	0.00195	CcSEcCtD
Thalidomide—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.000319	0.00194	CcSEcCtD
Thalidomide—Malaise—Vinblastine—head and neck cancer	0.000318	0.00193	CcSEcCtD
Thalidomide—Vertigo—Vinblastine—head and neck cancer	0.000317	0.00193	CcSEcCtD
Thalidomide—PTGS1—trachea—head and neck cancer	0.000316	0.00672	CbGeAlD
Thalidomide—Leukopenia—Vinblastine—head and neck cancer	0.000315	0.00192	CcSEcCtD
Thalidomide—Pancytopenia—Fluorouracil—head and neck cancer	0.000315	0.00192	CcSEcCtD
Thalidomide—Deafness—Docetaxel—head and neck cancer	0.00031	0.00188	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000309	0.00188	CcSEcCtD
Thalidomide—Cardiac failure congestive—Docetaxel—head and neck cancer	0.000306	0.00186	CcSEcCtD
Thalidomide—Convulsion—Vinblastine—head and neck cancer	0.000305	0.00186	CcSEcCtD
Thalidomide—Hypertension—Vinblastine—head and neck cancer	0.000304	0.00185	CcSEcCtD
Thalidomide—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000303	0.00184	CcSEcCtD
Thalidomide—PTGS2—trachea—head and neck cancer	0.000302	0.00643	CbGeAlD
Thalidomide—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000298	0.00181	CcSEcCtD
Thalidomide—Pneumonia—Fluorouracil—head and neck cancer	0.000298	0.00181	CcSEcCtD
Thalidomide—Anaemia—Hydroxyurea—head and neck cancer	0.000297	0.00181	CcSEcCtD
Thalidomide—Discomfort—Vinblastine—head and neck cancer	0.000296	0.0018	CcSEcCtD
Thalidomide—Infestation—Fluorouracil—head and neck cancer	0.000296	0.0018	CcSEcCtD
Thalidomide—Infestation NOS—Fluorouracil—head and neck cancer	0.000296	0.0018	CcSEcCtD
Thalidomide—Atrial fibrillation—Docetaxel—head and neck cancer	0.000293	0.00178	CcSEcCtD
Thalidomide—Visual disturbance—Docetaxel—head and neck cancer	0.000293	0.00178	CcSEcCtD
Thalidomide—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000292	0.00177	CcSEcCtD
Thalidomide—Myocardial infarction—Fluorouracil—head and neck cancer	0.00029	0.00176	CcSEcCtD
Thalidomide—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.00029	0.00176	CcSEcCtD
Thalidomide—Dermatitis bullous—Docetaxel—head and neck cancer	0.00029	0.00176	CcSEcCtD
Thalidomide—Malaise—Hydroxyurea—head and neck cancer	0.00029	0.00176	CcSEcCtD
Thalidomide—CYP1A2—thyroid gland—head and neck cancer	0.000289	0.00614	CbGeAlD
Thalidomide—Stomatitis—Fluorouracil—head and neck cancer	0.000289	0.00175	CcSEcCtD
Thalidomide—Conjunctivitis—Fluorouracil—head and neck cancer	0.000288	0.00175	CcSEcCtD
Thalidomide—Leukopenia—Hydroxyurea—head and neck cancer	0.000288	0.00175	CcSEcCtD
Thalidomide—CYP2E1—lymphoid tissue—head and neck cancer	0.000286	0.00608	CbGeAlD
Thalidomide—CYP1A1—thyroid gland—head and neck cancer	0.000285	0.00605	CbGeAlD
Thalidomide—Cardiac failure—Docetaxel—head and neck cancer	0.000284	0.00173	CcSEcCtD
Thalidomide—Lethargy—Docetaxel—head and neck cancer	0.000283	0.00172	CcSEcCtD
Thalidomide—Thrombocytopenia—Vinblastine—head and neck cancer	0.000282	0.00171	CcSEcCtD
Thalidomide—Epistaxis—Fluorouracil—head and neck cancer	0.000279	0.0017	CcSEcCtD
Thalidomide—Convulsion—Hydroxyurea—head and neck cancer	0.000278	0.00169	CcSEcCtD
Thalidomide—Hyponatraemia—Docetaxel—head and neck cancer	0.000278	0.00169	CcSEcCtD
Thalidomide—Sinusitis—Fluorouracil—head and neck cancer	0.000278	0.00169	CcSEcCtD
Thalidomide—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000277	0.00169	CcSEcCtD
Thalidomide—Pain in extremity—Docetaxel—head and neck cancer	0.000277	0.00169	CcSEcCtD
Thalidomide—Agranulocytosis—Fluorouracil—head and neck cancer	0.000276	0.00168	CcSEcCtD
Thalidomide—Anorexia—Vinblastine—head and neck cancer	0.000274	0.00167	CcSEcCtD
Thalidomide—Migraine—Docetaxel—head and neck cancer	0.000273	0.00166	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000272	0.00165	CcSEcCtD
Thalidomide—Discomfort—Hydroxyurea—head and neck cancer	0.00027	0.00164	CcSEcCtD
Thalidomide—Rhinitis—Fluorouracil—head and neck cancer	0.000266	0.00162	CcSEcCtD
Thalidomide—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000264	0.00161	CcSEcCtD
Thalidomide—Pharyngitis—Fluorouracil—head and neck cancer	0.000264	0.0016	CcSEcCtD
Thalidomide—PTGS2—lymphoid tissue—head and neck cancer	0.000263	0.0056	CbGeAlD
Thalidomide—Oedema—Hydroxyurea—head and neck cancer	0.000262	0.00159	CcSEcCtD
Thalidomide—Ataxia—Docetaxel—head and neck cancer	0.000261	0.00159	CcSEcCtD
Thalidomide—Infection—Hydroxyurea—head and neck cancer	0.000261	0.00158	CcSEcCtD
Thalidomide—CYP2E1—thyroid gland—head and neck cancer	0.00026	0.00552	CbGeAlD
Thalidomide—Paraesthesia—Vinblastine—head and neck cancer	0.000258	0.00157	CcSEcCtD
Thalidomide—Dehydration—Docetaxel—head and neck cancer	0.000258	0.00157	CcSEcCtD
Thalidomide—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000257	0.00156	CcSEcCtD
Thalidomide—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000257	0.00156	CcSEcCtD
Thalidomide—Liver function test abnormal—Docetaxel—head and neck cancer	0.000256	0.00156	CcSEcCtD
Thalidomide—Skin disorder—Hydroxyurea—head and neck cancer	0.000255	0.00155	CcSEcCtD
Thalidomide—Dry skin—Docetaxel—head and neck cancer	0.000254	0.00155	CcSEcCtD
Thalidomide—Orthostatic hypotension—Docetaxel—head and neck cancer	0.000253	0.00154	CcSEcCtD
Thalidomide—CYP1A1—head—head and neck cancer	0.000253	0.00537	CbGeAlD
Thalidomide—Breast disorder—Docetaxel—head and neck cancer	0.000251	0.00152	CcSEcCtD
Thalidomide—PTGS1—thyroid gland—head and neck cancer	0.00025	0.00532	CbGeAlD
Thalidomide—Anorexia—Hydroxyurea—head and neck cancer	0.00025	0.00152	CcSEcCtD
Thalidomide—Decreased appetite—Vinblastine—head and neck cancer	0.00025	0.00152	CcSEcCtD
Thalidomide—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.00025	0.00152	CcSEcCtD
Thalidomide—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.00025	0.00152	CcSEcCtD
Thalidomide—Cramp muscle—Docetaxel—head and neck cancer	0.00025	0.00152	CcSEcCtD
Thalidomide—Pain—Vinblastine—head and neck cancer	0.000246	0.0015	CcSEcCtD
Thalidomide—Constipation—Vinblastine—head and neck cancer	0.000246	0.0015	CcSEcCtD
Thalidomide—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000245	0.00149	CcSEcCtD
Thalidomide—Dysphagia—Docetaxel—head and neck cancer	0.00024	0.00146	CcSEcCtD
Thalidomide—Arrhythmia—Fluorouracil—head and neck cancer	0.000237	0.00144	CcSEcCtD
Thalidomide—Feeling abnormal—Vinblastine—head and neck cancer	0.000237	0.00144	CcSEcCtD
Thalidomide—Bronchospasm—Docetaxel—head and neck cancer	0.000236	0.00143	CcSEcCtD
Thalidomide—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000235	0.00143	CcSEcCtD
Thalidomide—Alopecia—Fluorouracil—head and neck cancer	0.000235	0.00143	CcSEcCtD
Thalidomide—Dyspnoea—Hydroxyurea—head and neck cancer	0.000234	0.00142	CcSEcCtD
Thalidomide—Angina pectoris—Docetaxel—head and neck cancer	0.000233	0.00142	CcSEcCtD
Thalidomide—Somnolence—Hydroxyurea—head and neck cancer	0.000233	0.00142	CcSEcCtD
Thalidomide—Dyspepsia—Hydroxyurea—head and neck cancer	0.000231	0.0014	CcSEcCtD
Thalidomide—CYP2E1—head—head and neck cancer	0.000231	0.0049	CbGeAlD
Thalidomide—Decreased appetite—Hydroxyurea—head and neck cancer	0.000228	0.00139	CcSEcCtD
Thalidomide—Pancytopenia—Docetaxel—head and neck cancer	0.000228	0.00138	CcSEcCtD
Thalidomide—Abdominal pain—Vinblastine—head and neck cancer	0.000227	0.00138	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000226	0.00138	CcSEcCtD
Thalidomide—Fatigue—Hydroxyurea—head and neck cancer	0.000226	0.00138	CcSEcCtD
Thalidomide—Constipation—Hydroxyurea—head and neck cancer	0.000224	0.00136	CcSEcCtD
Thalidomide—Pain—Hydroxyurea—head and neck cancer	0.000224	0.00136	CcSEcCtD
Thalidomide—Neutropenia—Docetaxel—head and neck cancer	0.000224	0.00136	CcSEcCtD
Thalidomide—PTGS1—head—head and neck cancer	0.000222	0.00472	CbGeAlD
Thalidomide—Weight increased—Docetaxel—head and neck cancer	0.000218	0.00133	CcSEcCtD
Thalidomide—Vision blurred—Fluorouracil—head and neck cancer	0.000218	0.00133	CcSEcCtD
Thalidomide—Weight decreased—Docetaxel—head and neck cancer	0.000217	0.00132	CcSEcCtD
Thalidomide—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000216	0.00131	CcSEcCtD
Thalidomide—Pneumonia—Docetaxel—head and neck cancer	0.000215	0.00131	CcSEcCtD
Thalidomide—Anaemia—Fluorouracil—head and neck cancer	0.000214	0.0013	CcSEcCtD
Thalidomide—Infestation NOS—Docetaxel—head and neck cancer	0.000214	0.0013	CcSEcCtD
Thalidomide—Infestation—Docetaxel—head and neck cancer	0.000214	0.0013	CcSEcCtD
Thalidomide—PTGS2—head—head and neck cancer	0.000212	0.00451	CbGeAlD
Thalidomide—Hypersensitivity—Vinblastine—head and neck cancer	0.000212	0.00129	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000212	0.00129	CcSEcCtD
Thalidomide—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000211	0.00128	CcSEcCtD
Thalidomide—Renal failure—Docetaxel—head and neck cancer	0.00021	0.00128	CcSEcCtD
Thalidomide—Myocardial infarction—Docetaxel—head and neck cancer	0.000209	0.00127	CcSEcCtD
Thalidomide—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000209	0.00127	CcSEcCtD
Thalidomide—Stomatitis—Docetaxel—head and neck cancer	0.000208	0.00127	CcSEcCtD
Thalidomide—Conjunctivitis—Docetaxel—head and neck cancer	0.000208	0.00126	CcSEcCtD
Thalidomide—Body temperature increased—Hydroxyurea—head and neck cancer	0.000207	0.00126	CcSEcCtD
Thalidomide—Leukopenia—Fluorouracil—head and neck cancer	0.000207	0.00126	CcSEcCtD
Thalidomide—Asthenia—Vinblastine—head and neck cancer	0.000206	0.00125	CcSEcCtD
Thalidomide—Epistaxis—Docetaxel—head and neck cancer	0.000202	0.00123	CcSEcCtD
Thalidomide—Convulsion—Fluorouracil—head and neck cancer	0.0002	0.00122	CcSEcCtD
Thalidomide—Agranulocytosis—Docetaxel—head and neck cancer	0.000199	0.00121	CcSEcCtD
Thalidomide—Myalgia—Fluorouracil—head and neck cancer	0.000197	0.0012	CcSEcCtD
Thalidomide—Chest pain—Fluorouracil—head and neck cancer	0.000197	0.0012	CcSEcCtD
Thalidomide—Diarrhoea—Vinblastine—head and neck cancer	0.000197	0.0012	CcSEcCtD
Thalidomide—Discomfort—Fluorouracil—head and neck cancer	0.000195	0.00118	CcSEcCtD
Thalidomide—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000193	0.00118	CcSEcCtD
Thalidomide—Rhinitis—Docetaxel—head and neck cancer	0.000192	0.00117	CcSEcCtD
Thalidomide—Hepatitis—Docetaxel—head and neck cancer	0.000192	0.00117	CcSEcCtD
Thalidomide—Hypoaesthesia—Docetaxel—head and neck cancer	0.000191	0.00116	CcSEcCtD
Thalidomide—Confusional state—Fluorouracil—head and neck cancer	0.00019	0.00116	CcSEcCtD
Thalidomide—Pharyngitis—Docetaxel—head and neck cancer	0.00019	0.00116	CcSEcCtD
Thalidomide—Dizziness—Vinblastine—head and neck cancer	0.00019	0.00116	CcSEcCtD
Thalidomide—Urinary tract disorder—Docetaxel—head and neck cancer	0.000189	0.00115	CcSEcCtD
Thalidomide—Oedema peripheral—Docetaxel—head and neck cancer	0.000189	0.00115	CcSEcCtD
Thalidomide—Oedema—Fluorouracil—head and neck cancer	0.000189	0.00115	CcSEcCtD
Thalidomide—Asthenia—Hydroxyurea—head and neck cancer	0.000188	0.00114	CcSEcCtD
Thalidomide—Urethral disorder—Docetaxel—head and neck cancer	0.000188	0.00114	CcSEcCtD
Thalidomide—Infection—Fluorouracil—head and neck cancer	0.000188	0.00114	CcSEcCtD
Thalidomide—Nervous system disorder—Fluorouracil—head and neck cancer	0.000185	0.00113	CcSEcCtD
Thalidomide—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000185	0.00112	CcSEcCtD
Thalidomide—Visual impairment—Docetaxel—head and neck cancer	0.000185	0.00112	CcSEcCtD
Thalidomide—Tachycardia—Fluorouracil—head and neck cancer	0.000184	0.00112	CcSEcCtD
Thalidomide—Vomiting—Vinblastine—head and neck cancer	0.000183	0.00111	CcSEcCtD
Thalidomide—Erythema multiforme—Docetaxel—head and neck cancer	0.000181	0.0011	CcSEcCtD
Thalidomide—Headache—Vinblastine—head and neck cancer	0.00018	0.0011	CcSEcCtD
Thalidomide—Anorexia—Fluorouracil—head and neck cancer	0.00018	0.00109	CcSEcCtD
Thalidomide—Diarrhoea—Hydroxyurea—head and neck cancer	0.000179	0.00109	CcSEcCtD
Thalidomide—Eye disorder—Docetaxel—head and neck cancer	0.000179	0.00109	CcSEcCtD
Thalidomide—Cardiac disorder—Docetaxel—head and neck cancer	0.000178	0.00108	CcSEcCtD
Thalidomide—CYP1A1—lymph node—head and neck cancer	0.000177	0.00376	CbGeAlD
Thalidomide—Hypotension—Fluorouracil—head and neck cancer	0.000176	0.00107	CcSEcCtD
Thalidomide—Angiopathy—Docetaxel—head and neck cancer	0.000174	0.00106	CcSEcCtD
Thalidomide—Dizziness—Hydroxyurea—head and neck cancer	0.000173	0.00105	CcSEcCtD
Thalidomide—Immune system disorder—Docetaxel—head and neck cancer	0.000173	0.00105	CcSEcCtD
Thalidomide—Mediastinal disorder—Docetaxel—head and neck cancer	0.000173	0.00105	CcSEcCtD
Thalidomide—Chills—Docetaxel—head and neck cancer	0.000172	0.00105	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000172	0.00105	CcSEcCtD
Thalidomide—Arrhythmia—Docetaxel—head and neck cancer	0.000171	0.00104	CcSEcCtD
Thalidomide—Nausea—Vinblastine—head and neck cancer	0.000171	0.00104	CcSEcCtD
Thalidomide—Insomnia—Fluorouracil—head and neck cancer	0.000171	0.00104	CcSEcCtD
Thalidomide—Paraesthesia—Fluorouracil—head and neck cancer	0.00017	0.00103	CcSEcCtD
Thalidomide—Alopecia—Docetaxel—head and neck cancer	0.000169	0.00103	CcSEcCtD
Thalidomide—Dyspnoea—Fluorouracil—head and neck cancer	0.000168	0.00102	CcSEcCtD
Thalidomide—Mental disorder—Docetaxel—head and neck cancer	0.000168	0.00102	CcSEcCtD
Thalidomide—Somnolence—Fluorouracil—head and neck cancer	0.000168	0.00102	CcSEcCtD
Thalidomide—Malnutrition—Docetaxel—head and neck cancer	0.000167	0.00102	CcSEcCtD
Thalidomide—Vomiting—Hydroxyurea—head and neck cancer	0.000167	0.00101	CcSEcCtD
Thalidomide—Dyspepsia—Fluorouracil—head and neck cancer	0.000166	0.00101	CcSEcCtD
Thalidomide—Rash—Hydroxyurea—head and neck cancer	0.000165	0.00101	CcSEcCtD
Thalidomide—Dermatitis—Hydroxyurea—head and neck cancer	0.000165	0.001	CcSEcCtD
Thalidomide—Headache—Hydroxyurea—head and neck cancer	0.000164	0.000999	CcSEcCtD
Thalidomide—Decreased appetite—Fluorouracil—head and neck cancer	0.000164	0.000998	CcSEcCtD
Thalidomide—Dysgeusia—Docetaxel—head and neck cancer	0.000164	0.000994	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000163	0.000991	CcSEcCtD
Thalidomide—Back pain—Docetaxel—head and neck cancer	0.000162	0.000982	CcSEcCtD
Thalidomide—Pain—Fluorouracil—head and neck cancer	0.000161	0.000982	CcSEcCtD
Thalidomide—Muscle spasms—Docetaxel—head and neck cancer	0.000161	0.000976	CcSEcCtD
Thalidomide—Nausea—Hydroxyurea—head and neck cancer	0.000156	0.000947	CcSEcCtD
Thalidomide—Feeling abnormal—Fluorouracil—head and neck cancer	0.000156	0.000946	CcSEcCtD
Thalidomide—PTGS1—lymph node—head and neck cancer	0.000156	0.0033	CbGeAlD
Thalidomide—Anaemia—Docetaxel—head and neck cancer	0.000154	0.000938	CcSEcCtD
Thalidomide—Urticaria—Fluorouracil—head and neck cancer	0.00015	0.000912	CcSEcCtD
Thalidomide—Syncope—Docetaxel—head and neck cancer	0.00015	0.00091	CcSEcCtD
Thalidomide—Leukopenia—Docetaxel—head and neck cancer	0.000149	0.000909	CcSEcCtD
Thalidomide—Body temperature increased—Fluorouracil—head and neck cancer	0.000149	0.000908	CcSEcCtD
Thalidomide—PTGS2—lymph node—head and neck cancer	0.000149	0.00316	CbGeAlD
Thalidomide—Palpitations—Docetaxel—head and neck cancer	0.000148	0.000897	CcSEcCtD
Thalidomide—Loss of consciousness—Docetaxel—head and neck cancer	0.000147	0.000892	CcSEcCtD
Thalidomide—Cough—Docetaxel—head and neck cancer	0.000146	0.000886	CcSEcCtD
Thalidomide—Convulsion—Docetaxel—head and neck cancer	0.000145	0.00088	CcSEcCtD
Thalidomide—Hypertension—Docetaxel—head and neck cancer	0.000144	0.000877	CcSEcCtD
Thalidomide—Myalgia—Docetaxel—head and neck cancer	0.000142	0.000864	CcSEcCtD
Thalidomide—Chest pain—Docetaxel—head and neck cancer	0.000142	0.000864	CcSEcCtD
Thalidomide—Arthralgia—Docetaxel—head and neck cancer	0.000142	0.000864	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000141	0.000858	CcSEcCtD
Thalidomide—Hypersensitivity—Fluorouracil—head and neck cancer	0.000139	0.000846	CcSEcCtD
Thalidomide—Dry mouth—Docetaxel—head and neck cancer	0.000139	0.000845	CcSEcCtD
Thalidomide—Confusional state—Docetaxel—head and neck cancer	0.000137	0.000835	CcSEcCtD
Thalidomide—Oedema—Docetaxel—head and neck cancer	0.000136	0.000829	CcSEcCtD
Thalidomide—Infection—Docetaxel—head and neck cancer	0.000135	0.000823	CcSEcCtD
Thalidomide—Shock—Docetaxel—head and neck cancer	0.000134	0.000815	CcSEcCtD
Thalidomide—Nervous system disorder—Docetaxel—head and neck cancer	0.000134	0.000813	CcSEcCtD
Thalidomide—Pruritus—Fluorouracil—head and neck cancer	0.000134	0.000812	CcSEcCtD
Thalidomide—Thrombocytopenia—Docetaxel—head and neck cancer	0.000133	0.000811	CcSEcCtD
Thalidomide—Tachycardia—Docetaxel—head and neck cancer	0.000133	0.000809	CcSEcCtD
Thalidomide—Skin disorder—Docetaxel—head and neck cancer	0.000132	0.000805	CcSEcCtD
Thalidomide—Anorexia—Docetaxel—head and neck cancer	0.00013	0.00079	CcSEcCtD
Thalidomide—Diarrhoea—Fluorouracil—head and neck cancer	0.000129	0.000785	CcSEcCtD
Thalidomide—Hypotension—Docetaxel—head and neck cancer	0.000127	0.000774	CcSEcCtD
Thalidomide—Dizziness—Fluorouracil—head and neck cancer	0.000125	0.000759	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000124	0.000755	CcSEcCtD
Thalidomide—Insomnia—Docetaxel—head and neck cancer	0.000123	0.000749	CcSEcCtD
Thalidomide—Paraesthesia—Docetaxel—head and neck cancer	0.000122	0.000744	CcSEcCtD
Thalidomide—Dyspnoea—Docetaxel—head and neck cancer	0.000121	0.000739	CcSEcCtD
Thalidomide—Somnolence—Docetaxel—head and neck cancer	0.000121	0.000737	CcSEcCtD
Thalidomide—Vomiting—Fluorouracil—head and neck cancer	0.00012	0.00073	CcSEcCtD
Thalidomide—Dyspepsia—Docetaxel—head and neck cancer	0.00012	0.000729	CcSEcCtD
Thalidomide—Rash—Fluorouracil—head and neck cancer	0.000119	0.000724	CcSEcCtD
Thalidomide—Dermatitis—Fluorouracil—head and neck cancer	0.000119	0.000723	CcSEcCtD
Thalidomide—Decreased appetite—Docetaxel—head and neck cancer	0.000118	0.00072	CcSEcCtD
Thalidomide—Headache—Fluorouracil—head and neck cancer	0.000118	0.000719	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000118	0.000715	CcSEcCtD
Thalidomide—Fatigue—Docetaxel—head and neck cancer	0.000117	0.000714	CcSEcCtD
Thalidomide—Pain—Docetaxel—head and neck cancer	0.000117	0.000709	CcSEcCtD
Thalidomide—Constipation—Docetaxel—head and neck cancer	0.000117	0.000709	CcSEcCtD
Thalidomide—Feeling abnormal—Docetaxel—head and neck cancer	0.000112	0.000683	CcSEcCtD
Thalidomide—Nausea—Fluorouracil—head and neck cancer	0.000112	0.000682	CcSEcCtD
Thalidomide—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000111	0.000678	CcSEcCtD
Thalidomide—Abdominal pain—Docetaxel—head and neck cancer	0.000108	0.000655	CcSEcCtD
Thalidomide—Body temperature increased—Docetaxel—head and neck cancer	0.000108	0.000655	CcSEcCtD
Thalidomide—Hypersensitivity—Docetaxel—head and neck cancer	0.0001	0.00061	CcSEcCtD
Thalidomide—Asthenia—Docetaxel—head and neck cancer	9.78e-05	0.000595	CcSEcCtD
Thalidomide—Pruritus—Docetaxel—head and neck cancer	9.64e-05	0.000586	CcSEcCtD
Thalidomide—Diarrhoea—Docetaxel—head and neck cancer	9.32e-05	0.000567	CcSEcCtD
Thalidomide—Dizziness—Docetaxel—head and neck cancer	9.01e-05	0.000548	CcSEcCtD
Thalidomide—Vomiting—Docetaxel—head and neck cancer	8.66e-05	0.000527	CcSEcCtD
Thalidomide—Rash—Docetaxel—head and neck cancer	8.59e-05	0.000522	CcSEcCtD
Thalidomide—Dermatitis—Docetaxel—head and neck cancer	8.58e-05	0.000522	CcSEcCtD
Thalidomide—Headache—Docetaxel—head and neck cancer	8.54e-05	0.000519	CcSEcCtD
Thalidomide—Nausea—Docetaxel—head and neck cancer	8.09e-05	0.000492	CcSEcCtD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—AKT1—head and neck cancer	3.8e-05	0.000254	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—PIK3CA—head and neck cancer	3.77e-05	0.000252	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—YAP1—head and neck cancer	3.73e-05	0.000249	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—BCL2—head and neck cancer	3.68e-05	0.000246	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—UROD—head and neck cancer	3.63e-05	0.000243	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	3.61e-05	0.000242	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	3.6e-05	0.000241	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—AKT1—head and neck cancer	3.59e-05	0.00024	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—PIK3CA—head and neck cancer	3.57e-05	0.000239	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.56e-05	0.000238	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HRAS—head and neck cancer	3.55e-05	0.000237	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.53e-05	0.000236	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—BCL2—head and neck cancer	3.49e-05	0.000233	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—head and neck cancer	3.49e-05	0.000233	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—HRAS—head and neck cancer	3.49e-05	0.000233	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	3.48e-05	0.000232	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NAT2—head and neck cancer	3.35e-05	0.000224	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—HRAS—head and neck cancer	3.31e-05	0.000221	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	3.29e-05	0.00022	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	3.24e-05	0.000217	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	3.14e-05	0.00021	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—VEGFA—head and neck cancer	3.12e-05	0.000208	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—STAT3—head and neck cancer	3.08e-05	0.000206	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—AKT1—head and neck cancer	3.08e-05	0.000206	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—BCL2L1—head and neck cancer	3.05e-05	0.000204	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—PTEN—head and neck cancer	3.05e-05	0.000204	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	2.97e-05	0.000199	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MAPK3—head and neck cancer	2.95e-05	0.000197	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—DPYD—head and neck cancer	2.94e-05	0.000197	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—PTEN—head and neck cancer	2.93e-05	0.000196	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—AKT1—head and neck cancer	2.92e-05	0.000195	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—BCL2L1—head and neck cancer	2.9e-05	0.000194	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—PTEN—head and neck cancer	2.89e-05	0.000193	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.83e-05	0.000189	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	2.83e-05	0.000189	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	2.83e-05	0.000189	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	2.81e-05	0.000188	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MAPK1—head and neck cancer	2.8e-05	0.000188	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—EGFR—head and neck cancer	2.8e-05	0.000188	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	2.8e-05	0.000187	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—YAP1—head and neck cancer	2.79e-05	0.000187	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—PTEN—head and neck cancer	2.78e-05	0.000186	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NAT2—head and neck cancer	2.66e-05	0.000178	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—MAPK3—head and neck cancer	2.6e-05	0.000174	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.51e-05	0.000168	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NAT2—head and neck cancer	2.51e-05	0.000168	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NAT2—head and neck cancer	2.5e-05	0.000167	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CASP8—head and neck cancer	2.5e-05	0.000167	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—MAPK1—head and neck cancer	2.48e-05	0.000166	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—EGFR—head and neck cancer	2.48e-05	0.000166	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—MAPK3—head and neck cancer	2.47e-05	0.000165	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CDH1—head and neck cancer	2.47e-05	0.000165	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	2.45e-05	0.000164	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NOTCH1—head and neck cancer	2.4e-05	0.000161	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—EGFR—head and neck cancer	2.38e-05	0.000159	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—VEGFA—head and neck cancer	2.37e-05	0.000159	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	2.37e-05	0.000159	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CASP8—head and neck cancer	2.37e-05	0.000158	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NAT2—head and neck cancer	2.36e-05	0.000158	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—STAT3—head and neck cancer	2.35e-05	0.000157	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—MAPK1—head and neck cancer	2.35e-05	0.000157	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—EGFR—head and neck cancer	2.35e-05	0.000157	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CDH1—head and neck cancer	2.34e-05	0.000156	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—DPYD—head and neck cancer	2.33e-05	0.000156	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—EGFR—head and neck cancer	2.26e-05	0.000151	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—HRAS—head and neck cancer	2.25e-05	0.000151	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MAPK3—head and neck cancer	2.25e-05	0.00015	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—YAP1—head and neck cancer	2.22e-05	0.000148	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—DPYD—head and neck cancer	2.2e-05	0.000147	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—DPYD—head and neck cancer	2.19e-05	0.000147	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—PIK3CA—head and neck cancer	2.15e-05	0.000144	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—BCL2—head and neck cancer	2.14e-05	0.000143	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MAPK1—head and neck cancer	2.14e-05	0.000143	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EGFR—head and neck cancer	2.14e-05	0.000143	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	2.1e-05	0.00014	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—YAP1—head and neck cancer	2.09e-05	0.000139	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—YAP1—head and neck cancer	2.08e-05	0.000139	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—DPYD—head and neck cancer	2.07e-05	0.000139	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—PIK3CA—head and neck cancer	2.06e-05	0.000138	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.05e-05	0.000137	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—PIK3CA—head and neck cancer	2.04e-05	0.000136	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	2.03e-05	0.000136	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—BCL2—head and neck cancer	2.03e-05	0.000136	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	2e-05	0.000134	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—HRAS—head and neck cancer	1.99e-05	0.000133	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—AKT1—head and neck cancer	1.99e-05	0.000133	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—YAP1—head and neck cancer	1.97e-05	0.000131	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—PIK3CA—head and neck cancer	1.96e-05	0.000131	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NAT2—head and neck cancer	1.93e-05	0.000129	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HRAS—head and neck cancer	1.91e-05	0.000128	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HRAS—head and neck cancer	1.89e-05	0.000126	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL2—head and neck cancer	1.89e-05	0.000126	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	1.87e-05	0.000125	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	1.85e-05	0.000124	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.83e-05	0.000122	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HRAS—head and neck cancer	1.81e-05	0.000121	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL2—head and neck cancer	1.79e-05	0.00012	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—head and neck cancer	1.78e-05	0.000119	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PTEN—head and neck cancer	1.77e-05	0.000119	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOTCH1—head and neck cancer	1.77e-05	0.000118	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NAT2—head and neck cancer	1.76e-05	0.000118	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—AKT1—head and neck cancer	1.76e-05	0.000117	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—HRAS—head and neck cancer	1.72e-05	0.000115	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—DPYD—head and neck cancer	1.7e-05	0.000113	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—AKT1—head and neck cancer	1.69e-05	0.000113	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PTEN—head and neck cancer	1.68e-05	0.000113	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOTCH1—head and neck cancer	1.68e-05	0.000112	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TYMS—head and neck cancer	1.68e-05	0.000112	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—AKT1—head and neck cancer	1.67e-05	0.000111	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GSTM1—head and neck cancer	1.66e-05	0.000111	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—YAP1—head and neck cancer	1.61e-05	0.000108	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	1.6e-05	0.000107	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—AKT1—head and neck cancer	1.6e-05	0.000107	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—STAT3—head and neck cancer	1.59e-05	0.000106	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GPX1—head and neck cancer	1.59e-05	0.000106	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	1.58e-05	0.000106	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP1A1—head and neck cancer	1.57e-05	0.000105	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTEN—head and neck cancer	1.55e-05	0.000104	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—DPYD—head and neck cancer	1.55e-05	0.000103	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MAPK3—head and neck cancer	1.52e-05	0.000101	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—AKT1—head and neck cancer	1.51e-05	0.000101	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NAT2—head and neck cancer	1.51e-05	0.000101	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—STAT3—head and neck cancer	1.51e-05	0.000101	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.48e-05	9.88e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—YAP1—head and neck cancer	1.47e-05	9.81e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.45e-05	9.71e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MAPK1—head and neck cancer	1.44e-05	9.65e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EGFR—head and neck cancer	1.44e-05	9.65e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MAPK3—head and neck cancer	1.44e-05	9.62e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—STAT3—head and neck cancer	1.39e-05	9.3e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MAPK1—head and neck cancer	1.37e-05	9.15e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EGFR—head and neck cancer	1.37e-05	9.15e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TYMS—head and neck cancer	1.33e-05	8.9e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MAPK3—head and neck cancer	1.33e-05	8.88e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—DPYD—head and neck cancer	1.32e-05	8.83e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTM1—head and neck cancer	1.31e-05	8.79e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.29e-05	8.63e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.29e-05	8.62e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MAPK1—head and neck cancer	1.26e-05	8.45e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EGFR—head and neck cancer	1.26e-05	8.45e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GPX1—head and neck cancer	1.26e-05	8.42e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—YAP1—head and neck cancer	1.25e-05	8.38e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TYMS—head and neck cancer	1.25e-05	8.37e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PIK3CA—head and neck cancer	1.25e-05	8.37e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TYMS—head and neck cancer	1.25e-05	8.36e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP1A1—head and neck cancer	1.25e-05	8.34e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTM1—head and neck cancer	1.24e-05	8.28e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTM1—head and neck cancer	1.24e-05	8.26e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2—head and neck cancer	1.22e-05	8.15e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.21e-05	8.08e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOTCH1—head and neck cancer	1.19e-05	7.97e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCND1—head and neck cancer	1.19e-05	7.95e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PIK3CA—head and neck cancer	1.19e-05	7.94e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GPX1—head and neck cancer	1.19e-05	7.93e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GPX1—head and neck cancer	1.18e-05	7.91e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TYMS—head and neck cancer	1.18e-05	7.9e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP1A1—head and neck cancer	1.17e-05	7.85e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP1A1—head and neck cancer	1.17e-05	7.83e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTM1—head and neck cancer	1.17e-05	7.8e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—head and neck cancer	1.16e-05	7.75e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2—head and neck cancer	1.16e-05	7.74e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTEN—head and neck cancer	1.15e-05	7.67e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCND1—head and neck cancer	1.13e-05	7.54e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GPX1—head and neck cancer	1.12e-05	7.47e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.1e-05	7.37e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—head and neck cancer	1.1e-05	7.35e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PIK3CA—head and neck cancer	1.1e-05	7.33e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTEN—head and neck cancer	1.09e-05	7.28e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.05e-05	7.05e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—head and neck cancer	1.04e-05	6.93e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—STAT3—head and neck cancer	1.03e-05	6.86e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.02e-05	6.85e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—head and neck cancer	1.02e-05	6.84e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—head and neck cancer	1.01e-05	6.78e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—head and neck cancer	9.83e-06	6.58e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK3—head and neck cancer	9.8e-06	6.56e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—STAT3—head and neck cancer	9.73e-06	6.51e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—head and neck cancer	9.7e-06	6.49e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TYMS—head and neck cancer	9.66e-06	6.46e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	9.61e-06	6.43e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTM1—head and neck cancer	9.55e-06	6.39e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	9.42e-06	6.3e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—head and neck cancer	9.34e-06	6.24e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK1—head and neck cancer	9.33e-06	6.24e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGFR—head and neck cancer	9.32e-06	6.24e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK3—head and neck cancer	9.3e-06	6.22e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GPX1—head and neck cancer	9.14e-06	6.12e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	9.09e-06	6.08e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP1A1—head and neck cancer	9.05e-06	6.05e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—head and neck cancer	8.96e-06	5.99e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK1—head and neck cancer	8.85e-06	5.92e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGFR—head and neck cancer	8.85e-06	5.92e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TYMS—head and neck cancer	8.81e-06	5.89e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTM1—head and neck cancer	8.71e-06	5.82e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GPX1—head and neck cancer	8.34e-06	5.58e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP1A1—head and neck cancer	8.25e-06	5.52e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	8.21e-06	5.49e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTEN—head and neck cancer	8.14e-06	5.45e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CA—head and neck cancer	8.09e-06	5.41e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—head and neck cancer	7.83e-06	5.24e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PTEN—head and neck cancer	7.72e-06	5.16e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CA—head and neck cancer	7.68e-06	5.14e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TYMS—head and neck cancer	7.53e-06	5.03e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—head and neck cancer	7.49e-06	5.01e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTM1—head and neck cancer	7.44e-06	4.98e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	7.44e-06	4.97e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—head and neck cancer	7.43e-06	4.97e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GPX1—head and neck cancer	7.12e-06	4.77e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—head and neck cancer	7.1e-06	4.75e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP1A1—head and neck cancer	7.05e-06	4.72e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—head and neck cancer	6.98e-06	4.67e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—head and neck cancer	6.96e-06	4.66e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—STAT3—head and neck cancer	6.9e-06	4.62e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	6.78e-06	4.54e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—head and neck cancer	6.61e-06	4.42e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAPK3—head and neck cancer	6.59e-06	4.41e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—head and neck cancer	6.58e-06	4.4e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PTEN—head and neck cancer	6.46e-06	4.32e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAPK1—head and neck cancer	6.27e-06	4.2e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGFR—head and neck cancer	6.27e-06	4.2e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—head and neck cancer	6.27e-06	4.2e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTEN—head and neck cancer	6.08e-06	4.07e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTEN—head and neck cancer	6.07e-06	4.06e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	5.79e-06	3.88e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CA—head and neck cancer	5.74e-06	3.84e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTEN—head and neck cancer	5.74e-06	3.84e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CA—head and neck cancer	5.45e-06	3.64e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—head and neck cancer	5.38e-06	3.6e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—head and neck cancer	5.04e-06	3.37e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—head and neck cancer	4.91e-06	3.28e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTEN—head and neck cancer	4.69e-06	3.14e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—head and neck cancer	4.69e-06	3.14e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CA—head and neck cancer	4.56e-06	3.05e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—head and neck cancer	4.45e-06	2.98e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CA—head and neck cancer	4.29e-06	2.87e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CA—head and neck cancer	4.28e-06	2.87e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTEN—head and neck cancer	4.28e-06	2.86e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—head and neck cancer	4.19e-06	2.81e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CA—head and neck cancer	4.05e-06	2.71e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—head and neck cancer	3.73e-06	2.49e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTEN—head and neck cancer	3.66e-06	2.45e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—head and neck cancer	3.51e-06	2.35e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—head and neck cancer	3.5e-06	2.34e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CA—head and neck cancer	3.31e-06	2.22e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—head and neck cancer	3.31e-06	2.21e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CA—head and neck cancer	3.02e-06	2.02e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—head and neck cancer	2.71e-06	1.81e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CA—head and neck cancer	2.58e-06	1.73e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—head and neck cancer	2.47e-06	1.65e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—head and neck cancer	2.11e-06	1.41e-05	CbGpPWpGaD
